The Delhi High Court is likely to resume tomorrow the hearing on pleas by over 30 pharma majors, including Pfizer, Glenmark, Procter and Gamble (P&G) and Cipla, challenging the government’s decision to ban sale of some of their fixed dose combination medicines.
Justice Rajiv Sahai Endlaw, who has stayed operation of the government’s notification till March 21 and directed the Centre not to take coercive steps against these companies, is expected to resume hearing the matters tomorrow.
Read more from our special coverage on “PHARMA”
- Pharmaceutical sector posts 12% growth in February
- Pharma crusader Dinesh Thakur takes Indias drug regulators to court
- Kiran Mazumdar-Shaw backs move to have separate pharma ministry
Initially the interim relief was given on March 14 to Pfizer’s cough syrup ‘Corex’. Later the same was granted to over 30 companies, which also included Glaxo Smithkline, Reckitt Benckiser, Abbott Healthcare, Piramal, Lupin, Mankind Pharma and Wockhardt.
Apart from them, the other companies which have moved the high court are Alembic Pharmaceutical, Ajanta Pharma, Macleods Pharmaceuticals, Dr Reddy’s, Laborate Pharmaceuticals, Alkem Laboratories, Khandelwal Laboratories Pvt Ltd, Micro Lab Ltd, FDC Ltd, Coral Laboratories Ltd and Eris Lifesciences Pvt Ltd.
Some of the well-known medicines on which the ban on sale has been lifted include Pfizer’s Corexcough syrup, Glaxo’s Piriton expectorant, P&G’s Vicks Action 500 extra, Reckitt’s D’Cold, Piramal’s Saridon, Glenmark’s Ascoril and Alex cough syrups, Abbott’s Phensedyl cough syrup and Alembic’s Glycodin cough syrup.
In the petitions of some of the companies, also including Laboratories Griffon, Centaur Pharmaceuticals, Shreya Life Sciences, Geno Pharmaceuticals and Unichem Laboratories, where they have obtained licence from state authorities for the purpose of manufacturing, marketing, distribution and sale of the fixed dose combination drugs, the court passed a different order.
In such cases, the court while staying the effect of the notification, also allowed the government to take action under any other available law for sale of those drugs which are made, marketed, distributed or sold on licence from state authorities instead of Drugs Controller General of India(DCGI).
This order was passed after the Centre on March 18 said under the Drugs and Cosmetics Act and Rules, the companies after 1988 had to obtain licence from DCGI and those which have got licence from state bodies are not entitled for any interim relief.
In their pleas, the healthcare companies sought quashing
of the government’s March 10 notification banning over 300 fixed dose combination drugs, including cough syrup compositions on the ground that they involve “risk” to humans and safer alternatives were available.
The companies have contended that the decision was taken by the government without issuing them a show cause notice or granting them a hearing.
They have alleged that the notification was silent on the aspect as to which expert committee was appointed by Health Ministry to examine the safety and deficiency of the fixed dose combination drugs.
As per the notification, “On the basis of recommendations of an expert committee, the central government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of said drugs in the country